Clinical Trial Update: Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH [Phase 2]

View source ↗

Summary

Phase 2 dose exploration trial of GSK4532990 in participants with non-alcoholic fatty liver disease, including NASH or suspected NASH, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• GSK4532990

Snippet

Sponsor: GlaxoSmithKline | Conditions: Non-alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED